You are here: Home » Companies » News
Business Standard

Glenmark Pharma receives final approval from USFDA for antiplatelet drug

The approved product is a generic version of Aggrenox capsules of Boehringer Ingelheim Pharmaceuticals Inc.

Drugs  |  Glenmark  |  Aspirin

Press Trust of India  |  New Delhi 

Pharmaceuticals, drugs, pharma industry, medical, health, lab
Representative Image

Pharmaceuticals Monday said it has received final approval from the US health regulator for antiplatelet agents and extended-release Dipyridamole capsules.

The approved product is a generic version of Aggrenox capsules of Boehringer Ingelheim Pharmaceuticals Inc.

Pharmaceuticals Inc, USA has been granted final approval by the Food & Drug Administration (USFDA) for and extended-release Dipyridamole capsules in the strength of 25 mg/200 mg, the company said in a BSE filing.

Citing IQVIA sales data, said, the Aggrenox capsules, 25 mg/200 mg market achieved annual sales of approximately USD 165.6 million in the 12-month period ended March 2019.

The company said its current portfolio consists of 155 products authorised for distribution in the US and 58 Abbreviated New Drug Application (ANDA's) pending approval with the

Shares of Glenmark Pharma were trading 0.03 per cent higher at Rs 559.20 apiece on the BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, May 27 2019. 10:35 IST